(+961) 1 421 000 ext fadi.saade@usj.edu.lb
My long term interest is to work on the development of novel prophylactic immunotherapeutic approaches against infection diseases. My academic training and research experience have provided me with an excellent background in multiple biological disciplines including immunology, virology, biochemistry and biology. As a predoctoral student, my research focused on the development and the evaluation of novel DNA-based immunotherapeutic approaches for chronic hepatitis B therapy. Particularly, I have evaluated in vivo the benefits of cytokine co-administration (IL-2, IFN-g) with DNA vaccine targeting DHBV structural proteins (envelope, core), on the increase of the vaccine efficacy. I have also developed tools and initiated a “Prime-Boost” therapeutic protocol, associating priming with DNA vaccine targeting DHBV envelope with a boost with an avian adenovirus (CELO) targeting DHBV envelope and IFN-g. Overall, my PHD results led to a better understanding of the biological significance of covalently-closed circular DNA (cccDNA) persistence after resolution of chronic infection and to a significative improvement of the therapeutic efficacy of DNA vaccine targeting DHBV, which may contribute to the development of a vaccine against HBV. I have performed my first postdoctoral training of 1 year, on different projects implicating Cytomegalovirus. I have worked on the development of an humanized SCID mice as a host of human fetal placenta. In addition, I have contributed on the conception and development of a national multicentric clinical project based on the measure of T cell reactivity upon stimulation with CMV antigens in transplanted patients. I have worked as a Research Scientist at Vaxine Pty Ltd, a leading and very innovative company in Australia, on the development of prophylactic vaccines against Flu, Malaria, and a therapeutic vaccine against chronic hepatitis B. I have a teaching experience of more than 10 years, particularly immunology, virology, biochemistry and biology courses, always with good feedbacks from students
| Diplôme | Université | Pays | Année |
|---|---|---|---|
| Doctorat - Biochimie - Aspects Moleculaires | Université Claude Bernard (Lyon I) | France | 2008 |
| Communication orale | Université Claude Bernard (Lyon I) | France | 2005 |
| Expérimentation Animale Niveau I | Université Claude Bernard (Lyon I) | France | 2005 |
| Biochimie | Université Claude Bernard (Lyon I) | France | 2003 |
| Biochimie | Université Libanaise (UL) | Liban | 2002 |
Faculté des Sciences
| Enseignement universitaire hors USJ | Pays | Etablissement | Date début | Date fin |
|---|---|---|---|---|
| Ensignant - Professor Associate | Liban | Université Libanaise (UL) | 04/10/2013 | 04/11/2024 |
| Enseignant | Liban | Université Saint-Esprit- Kaslik (USEK) | 01/09/2013 | 04/11/2024 |
| Expérience professionnelle | Organisation | Date début | Date fin |
|---|---|---|---|
| Senior Researcher | Vaxine | 01/09/2010 | 05/05/2013 |
| Postdoc | Faculté de Médecine de Limoges | 11/03/2008 | 06/01/2010 |
Médecine et Santé
Vaccinology, Biotechnology, Immunology, Virology
1. Martin G, Ferrier B, Conjard A, Martin M, Nazarian M, Boghossian M, Saadé F, Mancuso C, Durozard D, Baverel G. Glutamine gluconeogenesis in the small intestine of 72 h-fasted adult rats is undetectable (Biochem J. 2007 Jan15 401(2): 465-73). 2. Narayan R, Buronfosse T, Schultz U, Chevallier-Gueyron P, Guerret S, Chevallier M, Saade F, Ndeboko B, Trepo C, Zoulim F, Cova L. Rise in gamma interferon expression during resolution of duck hepatitis B virus infection (J Gen Virol. 2006 Nov;87(Pt 11):3225-32). 3. Saade F, Buronfosse T, Pradat P, Abdul F Cova L. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes (Vaccine. 2008 Sep 19;26(40):5159-64). 4. Honda-Okubo Y, Saade F, Petrovsky N. Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses (Vaccine. 2012 Aug 3;30(36):5373-81). 5. Saade F, Buronfosse T, Zoulim F, Trepo C and Cova L. In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes (J Viral Hepatitis. 2013 Apr;20(4):e56-65). 6. Saade F, Honda-Okubo Y, Trec S, Petrovsky N. A novel hepatitis B vaccine containing AdvaxTM, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing (Vaccine - 2013 Apr 8;31(15):1999-2007). 7. Capitani M & Saade F (co-first author), Havas KM, Angeletti M, Concetti F, Agas D, Sabbieti MG, Concetti A, Venanzi FM, Petrovsky N (Curr Gene Ther. 2014;14(3):161-9) 8. Lucie Morère, Déborah Andouard, François Labrousse, Fadi Saade, Claude-Alain Calliste, Sébastien Cotin,Yves Aubard, William D Rawlinson,Françoise Esclaire,Sébastien Hantz,Marie-Cécile Ploy,Sophie Alain Ex vivo model of congenital cytomegalovirus infection and new combination therapies (Placenta - 2015; 36: 41-47) REVIEW ARTICLES (PEER REVIEWED) 1. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. (Expert Rev Vaccines. 2012 Feb;11(2):189-209) – Cited 73 times so far 2. Li L, Saade F, Petrovsky N.The future of human DNA vaccines. (J Biotechnology. 2012 Dec 31;162(2-3):171-82.). 3. Saade F, Gorski SA, Petrovsky N. Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. (Exp Rev Vaccines. 2012 Dec;11(12):1459-70). 4. Saade F, Petrovsky N et al. The design and discovery of novel vaccine adjuvants for the treatment of SARS-CoV-2. Expert Opinion on Drug Discovery (will be submitted soon) BOOK CHAPTERS 1. Zoulim F, Saade F, Buronfosse T, Abdul F and Cova L - Animal models for the study of HBV infection (Chapter 6 - Hepatitis B Virus - International Medical Press – 2008). 2. Saade F, Buronfosse T, Khawaja G, Guerret S, Chevallier M, Pradat P, Zoulim F, Cova L. Co-Administration of Gamma Interferon Gene with DNA Vaccine Expressing Duck Hepatitis B Virus (DHBV) Proteins Enhances Therapeutic Efficacy of DNA-Based Immunization in Chronic Virus Carriers (NOVA Publishers. DNA Vaccines: Types, Advantages and Limitations. 2011- pp. 119-130) 3. Saade F, Buronfosse T, Khawaja G, Guerret S, Jamard C, Chevallier M, Pradat P, Zoulim F, Cova L. Co-Administration of Gamma Interferon Gene with DNA Vaccine Expressing Duck Hepatitis B Virus (DHBV) Proteins Enhances Therapeutic Efficacy of DNA-Based Immunization in Chronic Virus Carriers (NOVA Publishers. Interferons: Characterization, Mechanism of Action and Clinical Applications. 2012).
• Prix du meilleur Poster - à la base de meilleurs resultats de jeunes chercheurs dans les regions Rhone-Alpes-Auvergne- 3eme journee de canceropole CLARA